ELCC 2022 - European Lung Cancer Congress 2022
Mar 30 - Apr 02, 2022 | PragueCzech Republic
LARVOL is not affiliated with European Lung Cancer Congress 2022 and all trademarks, logos, and brand names are property of their respective owners
Showing 64 abstracts linked to Trials
Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study
Discussion
Invited Discussant of 80O and 141OFurmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG)
Discussion
Invited Discussant of 1OSafety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy
Discussion
Invited Discussant of 157MO and 172MODurvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: characteristics of long-term survivors in the CASPIAN study
Discussion
Invited Discussant of 80O and 141OFinal OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC
Discussion
Invited Discussant of 2MO, 7MO and 8MOFirst-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small-cell lung cancer: Updated overall survival results from the phase 3 CameL-sq trial
Patient-reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON
Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC With PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up
Oritinib (SH-1028), a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: results of a single-arm phase II trial
Discussion
Invited Discussant of 2MO, 7MO and 8MOThe efficacy and safety of TQ-B3101 monotherapy in the first line treatment in patients with ROS1 positive non-small cell lung cancer
Discussion
Invited Discussant of 2MO, 7MO and 8MOFinal Overall Survival (OS) Data of Sintilimab Plus Pemetrexed (SPP) and Platinum as First-Line (1L) Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (AMnsqNSCLC) in the Phase 3 ORIENT -11 Study
Characteristics of clonal hematopoiesis (CH) in patients with non-small cell lung cancer (NSCLC): A retrospective analysis of plasma cell-free DNA (cfDNA) comprehensive genomic profiling
Determination of essential biomarkers in lung cancer: A real-world data study in Spain
Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results